To Örebro University

oru.seÖrebro University Publications
Planned maintenance
A system upgrade is planned for 10/12-2024, at 12:00-13:00. During this time DiVA will be unavailable.
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Extending treatment effects from a randomized trial using observational data
Karolinska Institutet, Solna, Sweden.
Harvard T. H. Chan School of Public Health, Boston MA, USA.
Örebro University, School of Medical Sciences.ORCID iD: 0000-0002-5846-345X
Uppsala University, Uppsala, Sweden.
Show others and affiliations
2022 (English)In: Pharmacoepidemiology and Drug Safety, ISSN 1053-8569, E-ISSN 1099-1557, Vol. 31, no Suppl. 2, p. 211-211, article id 474Article in journal, Meeting abstract (Other academic) Published
Abstract [en]

Background: To increase confidence in the use of observational data for extending inferences from randomized trials, one can first benchmark. That is, demonstrate the observational analysis can replicate an index trial's findings, before using the observational data to estimate what the trial could not.

Objectives: To benchmark an observational study designed to ask the questions to the TASTE trial against results from the TASTE trial itself. Then, if benchmarking is successful, use the observational data to extend the inferences made in the trial.

Methods: We use Swedish registry data to emulate a target trial similar to the TASTE randomized trial, which found no difference in the risk of death or myocardial infarction by 1 year with or without thrombus aspiration among individuals with ST-elevation myocardial infarction. We benchmark the emulation against the trial at 1 year, then extend the emulation's follow-up to 3 years and estimate effects in subpopulations underrepresented in the trial.

Results: Like TASTE, the observational analysis found no differences in risk of outcomes by 1 year between groups (risk difference 0.7 (0.7, 2.0) and0.2 (1.3, 1.0) for death and myocardial infarction respectively), so benchmarking was considered successful. We additionally show no difference in risk of death or myocardial infarction by 3 years, or within subpopulations by 1 year.

Conclusions: Benchmarking before using observational data to extend treatment effects from a randomized trial allows us to understand if the observational data can be trusted to deliver valid estimates of treatment effects.

Place, publisher, year, edition, pages
John Wiley & Sons, 2022. Vol. 31, no Suppl. 2, p. 211-211, article id 474
National Category
Pharmacology and Toxicology
Identifiers
URN: urn:nbn:se:oru:diva-102038ISI: 000859084401020OAI: oai:DiVA.org:oru-102038DiVA, id: diva2:1708040
Conference
38th International Conference on Pharmacoepidemiology: Advancing Pharmacoepidemiology and Real-World Evidence for the Global Community (ICPE 2022), Copenhagen, Denmark, August 26–28, 2022
Available from: 2022-11-02 Created: 2022-11-02 Last updated: 2024-01-16Bibliographically approved

Open Access in DiVA

No full text in DiVA

Authority records

Fröbert, Ole

Search in DiVA

By author/editor
Fröbert, Ole
By organisation
School of Medical Sciences
In the same journal
Pharmacoepidemiology and Drug Safety
Pharmacology and Toxicology

Search outside of DiVA

GoogleGoogle Scholar

urn-nbn

Altmetric score

urn-nbn
Total: 177 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf